NNVC
NanoViricides Inc
NYSE MKT: NNVC · HEALTHCARE · BIOTECHNOLOGY
$1.24
+1.64% today
Updated 2026-04-30
Market cap
$26.99M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $2
Volume
0.2M
NanoViricides Inc (NNVC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+28.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+20.9%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+2.0%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+11.9%
2025-12-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-11 | $-0.11 | +21.4% | $1.01 | $0.93 | -7.9% |
| 2025-12-03 | $-0.14 | +25.0% | $1.09 | $1.22 | +11.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.14 | $-0.11 | +21.4% | — | — |
| 2025-09-30 | $-0.18 | $-0.14 | +25.0% | — | — |
| 2025-06-30 | $-0.20 | $-0.12 | +40.0% | — | — |
| 2025-03-31 | $-0.19 | $-0.14 | +27.2% | — | — |
| 2024-12-31 | $-0.18 | $-0.14 | +22.7% | — | — |
| 2024-09-30 | $-0.17 | $-0.23 | -34.1% | — | — |
| 2024-06-30 | $-0.31 | $-0.19 | +38.7% | — | — |
| 2024-03-31 | $-0.19 | $-0.16 | +15.8% | — | — |
| 2023-12-31 | $-0.19 | $-0.18 | +5.3% | — | — |
| 2023-09-30 | $-0.17 | $-0.15 | +11.8% | — | — |
| 2023-06-30 | $-0.17 | $-0.31 | -79.5% | — | — |
Frequently asked questions
Has NanoViricides Inc beaten earnings estimates?
NanoViricides Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +28.4% over the last 4 quarters.
How does NNVC stock react to earnings?
NNVC stock has moved an average of +2.0% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.